Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermediate-dose cytarabine consolidation regimens for AML
ChiCTR-TRC-13003443Phase 2Completed
- Sponsor
- Department of Hematology, Second Affiliated Hospital of Dalian Medical University
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Department of Hematology, Second Affiliated Hospital of Dalian Medical University. Primary endpoints: 3-year overall survival and 3-year disease-free survival. Started Sep 2013; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-TRC-13003443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003443.